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a  b  s  t  r  a  c  t
Dengue  has  become  the most  rapidly  expanding  mosquito-borne  infectious  disease  on  the planet,  sur-
passing  malaria  and  infecting  at least  390 million  people  per  year.  There  is no effective  treatment  for
dengue  illness  other  than  supportive  care,  especially  for severe  cases.  Symptoms  can  be mild  or  life-
threatening  as  in  dengue  hemorrhagic  fever  and  dengue  shock  syndrome.  Vector  control  has  been only




lent  dengue  vaccines  is an  attractive  addition  to  prevent  disease  or  minimize  the  possibility  of epidemics.
There  are currently  no  licensed  dengue  vaccines.  This  review  summarizes  the  current  status  of  all  dengue
vaccine  candidates  in clinical  evaluation.  Currently  ﬁve  candidate  vaccines  are  in human  clinical  trials.
One  has  completed  two  Phase  III trials,  two are  in  Phase  II trials,  and  three  are  in  Phase  I testing.
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. Introduction
Dengue virus (DENV) is a mosquito-borne ﬂavivirus that infects
t least 390 million people per year [1]. It is estimated that nearly
alf the world’s population is at risk for dengue infection [1]. A
ecent report from the Pan American Health Organization points
ut that reported dengue cases in the America rose by a factor of ﬁve
n the last ten years [2]. The primary mosquito vector for dengue,
edes aegypti, continues to spread widely and into new habitats
ue to increased urbanization and climate change. The less efﬁcient
ector A. albopictus is also rapidly expanding its habitat [3]. Dengue
as become the most rapidly expanding mosquito-borne infectious
isease on the planet, surpassing malaria.
Dengue infection and illness are caused by four distinct DENV
erotypes that cross-react immunologically. Infection with a par-
icular serotype is believed to result in life-long immunity to that
erotype and cross-protection to the other serotypes for up to two
ears [4]. People who have had a single primary infection have been
bserved to have a higher risk of severe dengue including dengue
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hemorrhagic fever (DHF) and dengue shock syndrome (DSS) upon
a second infection, a phenomenon often attributed to antibody
enhancement [5]. Infants with waning maternal dengue antibodies
have been observed to be at higher risk of DHF and DSS com-
pared to infants with no maternal dengue antibodies [6]. There is
no speciﬁc effective antiviral treatment for dengue illness other
than supportive care, especially for severe cases. Good case man-
agement of severe dengue cases can greatly reduce the death rate.
The only current means for dengue control are various forms of
vector control. However, vector control has been only partially suc-
cessful in reducing dengue disease burden [7,8]. More effective
vector control measures such as integrated vector control, the use
of Wolbachia infection in mosquitoes [9], or genetically modiﬁed
mosquitoes [10] could eventually prove effective, but implementa-
tion of these methods is probably years into the future. Against this
backdrop of an expanding dengue pandemic and no effective means
to mitigate spread, the potential use of safe and effective tetrava-
lent dengue vaccines is a very attractive addition to dengue control.
Even if only partially effective, the use of dengue vaccines could be
highly beneﬁcial in blunting dengue epidemics, and for increasing
population-level immunity to the level where vector control could
be more effective.
Dengue vaccines could have beneﬁcial individual-level effects
by reducing the probability of infection given exposure to an
infected mosquito, i.e., vaccine efﬁcacy (VE) for susceptibility to
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Summary of dengue vaccine candidates in clinical development.
Vaccine
candidate
Manufacturer Vaccine type Mechanism of attenuation or inactivation Clinical phase References
CYD Sanoﬁ Pasteur Live attenuated Yellow fever vaccine backbone, premembrane and
envelope proteins from wildtype dengue virus
III [11–34]
DENVax Takeda Live attenuated Wildtype DEN2 strain attenuated in primary dog
kidney cells and further attenuated by mutation in
NS3 gene
II [35–43]
TV003/TV005 NIAID and Butantan Institute Live attenuated Wildtype strains with genetic mutations II [44–59]
TDENV PIV GSK and WRAIR Puriﬁed inactivated Formalin inactivated I [60–63]
V180 Merck Recombinant subunit Wildtype premembrane and truncated envelope
protein via expression in the Drosophila S2 cell
expression system
I [64,65]
D1ME100 NMRC DNA Premembrane and envelope proteins of DENV1 are















































nfection, reducing the probability of clinical disease given infection
r the probability of severe disease, i.e., VE for disease progres-
ion, or reducing the probability that an infected vaccinated person
ill transmit virus to a mosquito that bites him or her, i.e., VE for
irect transmission. In addition, with increasing vaccine coverage
n a population, vaccines could reduce the overall transmission
n the entire community, even to unvaccinated people, and thus
ave indirect or herd effects. All of these individual-level and
ommunity-level vaccine effects need to be taken into account
hen assessing the potential effectiveness and impact of dengue
accines. In this paper, we summarize properties of the dengue
accine candidates that are currently in some stage of clinical devel-
pment with vaccine trials in phases I–III (Table 1). We  note that
nly one vaccine has made it to double-blinded, placebo-control,
hase III vaccine trials, the Sanoﬁ Pasteur tetravalent chimeric
ellow-fever dengue (CYD) vaccine, as summarized below.
. Overview of vaccines in clinical development
.1. CYD (Sanoﬁ Pasteur)
Sanoﬁ Pasteur’s CYD vaccine is a live attenuated tetravalent
himeric vaccine. For each of the four dengue serotypes the pre-
embrane and envelope proteins from a wild type dengue virus are
ubstituted into the yellow fever (YF) 17D vaccine backbone [11].
he ﬁrst CYD clinical trial in healthy adults, which only assessed the
erotype 2 vaccine strain, found a high dose (5 log10 plaque form-
ng units (PFU)) elicited a strong neutralizing antibody response to
ENV2. Participants previously given YF vaccine seroconverted to
ll 4 dengue serotypes [12]. This multivalent neutralizing antibody
esponse was further observed in a phase IIa study in Australian
dults. To safely mimic  the dengue endemic target population, par-
icipants were vaccinated with YF vaccine or monovalent DENV1
r DENV2 vaccines one year before vaccinating with one dose
f tetravalent CYD. In ﬂavivirus-naïve participants, no participant
eroconverted to DENV1 by day 28 and only ∼22% had serocon-
erted to DENV2 (compared to ∼60% who seroconverted to DENV3
nd ∼70% who seroconverted to DENV4). The pre-existing ﬂa-
ivirus immunity increased neutralizing antibody response to all
our serotypes compared to ﬂavivirus-naïve participants [13].
The ﬁrst phase I study in children was conducted in the dengue
on-endemic region of Mexico City. Children aged 2 to 17 years
eceived three doses at 0, 3.5 and 12 months. Seropositivity rates
fter the ﬁrst dose were lowest for DEN1 and DEN2 [14]. A phase I
rial conducted in the Philippines, where both dengue and Japanese
ncephalitis are endemic, compared the immunogenicity of three
oses of CYD at 0, 3.5 and 12 months to only two  doses of CYDgalovirus promoter/enhancer of the
d vector VR1012
at 3.5 and 12 months. 85% of participants were seropositive to all
four serotypes regardless of the dosing schedule [15]. Early stud-
ies in ﬂavivirus-naïve adults compared a 0, 4, and 12–15 month
dosing schedule to a 2-dose schedule at 4 and 12–15 months.
In the three-dose group all participants seroconverted to all four
serotypes, while in the two  dose group 92% seroconverted to DENV1
and 100% seroconverted to DENV2–4 [16]. To limit viral interfer-
ence and subsequently increase immunogenicity and balance the
immune response in naïve populations, Sanoﬁ moved forward with
a 0, 6, and 12 month dosing schedule.
Several phase II studies have been conducted throughout the
world in adults and children. In the dengue-naïve population of
Singapore, immunogenicity data on 600 participants found that
after three doses of CYD at 0, 6, and 12 months 66.5% of those
vaccinated were seropositive to all four serotypes, though serocon-
version rates were higher in children [17]. A study of 300 2–11 year
olds in Peru with 82% of children YF seropositive at baseline found
94.1% to be seropositive to all four serotypes after the third CYD
dose. The overall antibody geometric mean titer (GMT) was  higher
in participants who  were dengue seropositive at baseline com-
pared to participants who  were dengue seronegative at baseline
[18]. A trend of higher seroconversion and GMT  antibody response
in baseline Flavivirus seropositive participants has also been seen
in phase II studies in Brazil [19], Malaysia [20], and Latin America
(Colombia, Honduras, Mexico, Puerto Rico) [21]. A phase IIb proof-
of-concept trial was conducted in 4002 Thai children aged 4–11.
Children were randomized to placebo or vaccine with three doses
at 0, 6, and 12 months. This was the ﬁrst trial with a primary end-
point of vaccine efﬁcacy and secondary endpoints including safety
and immunogenicity. In this study the per-protocol vaccine efﬁcacy
of CYD against all serotypes was 30.2% and not statistically signiﬁ-
cant (95% conﬁdence interval (CI): −13.4–56.6) [22]. Efﬁcacy after
at least one injection against serotypes DENV1, DENV3, and DENV4
was statistically signiﬁcant (VE = 61.2%, 81.9%, 90.0%, respectively),
though the trial was  not designed or powered for this post-hoc anal-
ysis. Vaccine efﬁcacy against DENV2 was not signiﬁcant (VE = 3.5%,
95%CI: −59.8–40.5). The immunogenicity sub study in only 296
subjects found increased GMT  (as measured by plaque reduction
neutralization test (PRNT)) after the ﬁrst, second and third doses for
all serotypes. Investigators suggest that immunogenicity as mea-
sured by PRNT may  not indicate protection, the GMTs were not high
enough to protect this particular lineage of viruses, or there was
an antigenic mismatch between the vaccine serotype 2 virus and
the circulating DENV2 causing disease in Thailand. Further investi-
gations showed that antigenic diversity between vaccine virus and
wild type did not impact neutralization and was likely not a cause of
the low efﬁcacy [23]. Additional phase II safety and immunogenic-
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25], and India [26]. Phase II studies further examining immune
nterference by investigating 0, 2, and 12 month dosing schedules
re ongoing [27,28].
Two large-scale phase III efﬁcacy trials in Latin America (Brazil,
olombia, Honduras, Mexico, Puerto Rico) and Asia (Indonesia,
alaysia, Philippines, Thailand, Vietnam) have been completed
29–32]. In both studies participants were randomized 2:1 to vac-
ine or placebo for 3 doses at 0, 6, and 12 months with a primary
utcome of vaccine efﬁcacy against symptomatic, virologically-
onﬁrmed dengue more than 28 days after the third injection. In
he study conducted in 5 countries in Asia among 10,278 chil-
ren aged 2–14 years the per-protocol vaccine efﬁcacy estimate
as 56.5% (95%CI: 43.8–66.4). Two hundred and ﬁfty dengue cases
ere identiﬁed in the per-protocol analysis but 595 children were
dentiﬁed with dengue starting after baseline. The vaccine efﬁcacy
fter 3 doses for dengue hemorrhagic fever, severe dengue and hos-
italized dengue was also statistically signiﬁcant (88.5% (95%CI:
8.2–97.9), 80.8% (95%CI: 42.7–94.7), 67.2% (95%CI: 50.3–78.6),
espectively). Similar to the phase IIb study in Thailand, while
mmunogenicity was high for all serotypes, the serotype speciﬁc
fﬁcacy for DENV2 in this study was not statistically signiﬁcant
hile efﬁcacy for serotypes 1, 3 and 4 was signiﬁcant.
In the immunogenicity subset, more than 67% of participants
ere seropositive for any dengue serotype at baseline. In an
xploratory analysis the vaccine efﬁcacy in the baseline dengue
eropositive group was 74.3% (95%CI: 53.2–86.3) and 35.5% (95%CI:
26.8–66.7) in the baseline dengue seronegative group [33]. Simi-
arly, younger children were found to have a lower vaccine efﬁcacy,
ossibly due to their limited exposure to dengue compared to older
hildren, suggesting the vaccine boosts existing naturally-acquired
mmunity [34].
In the Latin American study, 20,869 children aged 9–16 years
ere randomized 2:1 to vaccine or placebo for 3 doses at 0, 6
nd 12 months. The per-protocol vaccine efﬁcacy estimate was
0.8% (95%CI: 52.0–68.0). In the modiﬁed per-protocol analysis for
erotype-speciﬁc vaccine efﬁcacy, all serotypes showed a statis-
ically signiﬁcant efﬁcacy ranging from 42.3% for DEN2 to 77.7%
or DENV4. In the immunogenicity subset 79% of participants were
eropositive for any dengue serotype at baseline. An exploratory
nalysis found vaccine efﬁcacy among children seropositive at
aseline to be higher (83.7% 95%CI: 62.2–93.7) compared to chil-
ren seronegative at baseline (43.2% 95%CI: −61.5–80.0) [32].
accine efﬁcacy also varied by country (77.5% in Brazil to 31.3%
n Mexico) as the dominant DENV serotype circulating in countries
iffered (DENV4 in Brazil, DENV1 and DENV2 in Mexico).
.2. DENVax (Inviragen/Takeda)
The DENVax vaccine candidate contains a mixture of whole live-
ttenuated DENV2 and chimeric DENV1, DENV3, DENV4 based on
he attenuated DENV2 backbone. These are based on the previously
eveloped DEN-2 PDK-53 vaccine. A wild-type DEN2 strain from a
ymptomatic patient in Thailand was attenuated by 53 serial pas-
ages in primary dog kidney (PDK) cells. The DEN-2 PDK-53 vaccine
as originally derived at Mahidol University in Bangkok, Thailand,
nd has been tested preclinically and clinically since the late 1980s.
he current DENVax vaccine is further attenuated by a mutation in
he NS3 gene. DENVax vaccine strains for serotypes 1, 3 and 4 were
reated by replacing the premembrane and envelope proteins of
he DEN-2 PDK-53-V with genes from the respective dengue virus
ild type serotype [35].
There are currently several ongoing and completed phase I andhase II trials in dengue naïve and endemic populations. Two phase
 studies in the US and in a dengue non-endemic region of Colombia
ssessed low and high doses of DENVax and different routes of
dministration (subcutaneous or intradermal) in healthy adults at 33 (2015) 3293–3298 3295
0 and 3 months [36,37]. In Colombia, both formulations and admin-
istration routes were safe and induced neutralizing antibody to all
serotypes [38]. Two  additional phase I studies compared vaccine
administration via the traditional needle-syringe mechanism, a
needle-less injector, and a needle-free Pharmaject Injector [39,40].
Different formulations of the vaccine are also being evaluated [41].
An ongoing phase II study of 344 children and adults assessing the
safety and immunogenicity of the vaccine in Colombia, Puerto Rico,
Singapore and Thailand started in 2011 [42]. In late 2014 a phase
II study in 1800 children in Asia and Latin America commenced to
examine immunogenicity of 3 dosing schedules (day 0 only, 0 and
3 months, day 0 and 1 year) [43].
2.3. TV003/TV005 (NIAID)
The National Institute of Allergy and Infectious Diseases,
National Institutes of Health (NIAID) took a different approach in
examining the potential vaccine strains to be incorporated into
their tetravalent dengue vaccine candidate. To ensure that each
serotype speciﬁc strain included in the vaccine was safe, infectious,
and immunogenic, NIAID tested several monovalent vaccines with
similar genetic mutations in ﬂavivirus naïve participants. By using
strains with the same genetic mutation researchers attempted to
create strains that were kinetically similar. This would allow for
a balanced humoral response and could reduce immune interfer-
ence. The vaccine strains for serotypes 1 and 4 are based on a wild
type DENV1 and DENV4 strains with a 30 nucleotide deletion in the
3′ untranslated region (rDEN130 and rDEN430). Early studies
showed both monovalent vaccines to be highly immunogenic [44]
with some hepatotoxicity in rDEN430  when given at a dose of
5 log10 PFU [45,46]. This resolved when the vaccine was given at
lower doses (3 log10 PFU–1 log10 PFU). Attempts were made to gen-
erate a less toxic/reactogenic form of the serotype 4 strain, such as
incorporating additional mutations [47,48]. NIAID moved forward
with the original monovalent vaccine at a dose of 3 log10 PFU.
30 mutations in wild type dengue serotypes 2 and 3 were
attempted in animal models, but were not found to be as atten-
uated as serotypes 1 and 4, and other methods of attenuation were
examined. The vaccine for serotype 2, rDEN2/430(ME) uses the
serotype 4 vaccine strain (rDEN430) and replaces the premem-
brane and envelope proteins of DENV2. This method resulted in a
monovalent vaccine that was safe and induced 100% seroconver-
sion to DENV2 [49]. The serotype 3 strain, rDEN330/31, is based
on DENV3 with the 30 nucleotide deletion similar to the other
strains, but an additional 31 nucleotides are removed upstream of
the 30 mutation [50]. A different dengue 3 vaccine strain which
inserted the 3′ untranslated region of the dengue serotype 4 vac-
cine candidate into DENV3 virus was also examined, but tetravalent
vaccine studies showed a vaccine with rDEN330/31 induced a
broader neutralizing antibody response [51].
Similar to other research groups, monovalent vaccines were
evaluated when administered to participants with preexisting
heterotypic DENV antibodies, induced by other monovalent dengue
vaccines, as a surrogate for naturally acquired infection. The hete-
rotypic vaccine induced a broad neutralizing antibody response
to all four serotypes [52]. Different monovalent vaccine candi-
dates were combined into ﬁve different tetravalent admixtures
(TV001–TV005) to assess immunogenicity and safety of a single
tetravalent dose. Each component was given at a dose of 3 log10 PFU
as a single subcutaneous dose with the exception of the DENV2
component of TV005 which was given at a dose of 4 log10 PFU.
TV003, which includes the vaccine strains previously discussed,
elicited the most balanced and broad antibody response with 45% of
participants seroconverting to all four serotypes after only 1 dose.
Seroconversion rates were high for DENV1, DENV3, and DENV4
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eroconversion was deﬁned to study day 42 but it was noted that
ntibody titers in some vaccine recipients continued to increase
fter study day 42 and for that reason, seroconversion rates were
onitored out to study day 90 in future trials. Sixty two per-
ent of those vaccinated with TV003 developed a mild, transient,
aculopapular rash. The rash was asymptomatic in all of those who
eveloped a rash [53].
In a follow-on trial, the safety and immunogenicity of TV003
as compared with that of a second formulation containing a 10-
old higher dose of the rDEN2/430 component, TV005 [53]. A
ingle dose of TV003 induced seroconversion rates to DENV1–4 of
2%, 76%, 97%, and 100%. Seventy-four percent of TV003 recipients
ounted a tetravalent response. A single dose of TV005 induced
eroconversion rates to DENV1–4 of 92%, 97%, 97%, and 97% and an
verall tetravalent response in 90% of recipients. In both TV003 and
V005 vaccinated groups African Americans had a lower tetrava-
ent seroconversion rate (53%) compared to non-African Americans
86%).
A new serotype 2 vaccine strain, rDEN2 30-7169, is also being
xamined to ﬁnd a vaccine strain with increased immunogenic-
ty when part of the tetravalent vaccine [54–56]. A phase I study
xamining the durability of the antibody response of TV003 to 12
onths is currently being conducted in dengue naïve adults [57].
articipants will be challenged with a second dose of vaccine at 12
onths to evaluate the protection induced by the vaccine against
nfection with the vaccine given 12 months later. A phase II study
n Thailand started in early 2015 to examine safety and immune
esponse of two doses of TV003 at 0 and 6 months in adults and
hildren [58]. TV005 is currently being evaluated in a phase II age
e-escalation trial in Thailand. In collaboration with the Butantan
nstitute, a phase II study of TV003 in Brazil started in October
013. Safety and immunogenicity of one dose (liquid or lyophilized)
f TV003 in dengue naïve and dengue primed individuals will be
valuated with results completed by December 2018 [59].
.4. TDENV PIV (GSK)
TDEN PIV is a tetravalent puriﬁed inactivated vaccine currently
eing evaluated jointly by GSK and Walter Reed Army Institute of
esearch (WRAIR). A phase I study of high and low doses in ﬂa-
ivirus naïve adults has already been conducted in the US [60].
dditionally, GSK is testing TDEN PIV with several adjuvants used
n other vaccines. Aluminum hydroxide, AS01E, and AS03B have
lready been assessed as adjuvants with GSK’s hepatitis B, malaria,
nd pandemic inﬂuenza vaccines, respectively. A recent phase I trial
xamined the safety and immunogenicity of TDEN PIV with these
djuvants at different doses in the US [61] and another trial, sched-
led to end December 2016, is examining the vaccine in Puerto
ican adults, a dengue primed population [62]. A prime-boost strat-
gy with TDEN PIV and a live attenuated dengue vaccine is also
nder evaluation in a phase II trial [63].
.5. V180 (Merck)
V180 is a recombinant subunit vaccine based on the dengue wild
ype premembrane and truncated envelope protein (DEN-80E) via
xpression in the Drosophila S2 cell expression system [64]. The
urrent phase I trial, scheduled to end January 2015, examines V180
t low, medium, and high doses in healthy adults at 0, 1 and 2
onths. The vaccine is being assessed without an adjuvant, and
ith adjuvants ISOCOMATRIX and alhydrogel [65]..6. D1ME100 (NMRC)
D1ME100 is a monovalent plasmid DNA vaccine currently being
xamined at the Naval Medical Research Center (NMRC). The 33 (2015) 3293–3298
premembrane and envelope proteins of DENV1 are being expressed
under control of the human cytomegalovirus promoter/enhancer of
the plasmid vector VR1012 [66]. The ﬁrst phase I proof-of-concept
trial assessed the vaccine in ﬂavivirus naïve adults via intramuscu-
lar injection using a needle free Biojector 2000 at 0, 1 and 5 months
at high and low doses [67]. The vaccine was  safe but there was no
neutralizing antibody response to the low dose, and only 42% of par-
ticipants with the high dose produced an antibody response that
was not sustained long term. Future studies of this DNA vaccine
include using alternate delivery methods, a prime boost mecha-
nism, novel adjuvants or unique platforms for DNA vaccines.
3. Discussion
We  have described the dengue vaccine pipeline that includes
vaccines in phases I–III in clinical development. The dengue vac-
cine constructs in some phase of clinical trials are live attenuated
chimeric, sub-unit proteins, puriﬁed inactivated, and plasmid DNA.
Other constructs such as virus-vectored, DNA and virus-like parti-
cles are still being preclinically tested.
There are several phase I–IIa studies examining vaccines for
safety and immunogenicity. NIAID has tested several monova-
lent vaccines individually and in combination to produce a highly
immunogenic vaccine with little viral interference [52,53]. Novel
adjuvants and routes of administration are also being assessed in
inactivated and recombinant subunit vaccines [61,62,65]. Results
of these early phase I studies are still unknown. As we learn more
about the importance of dengue immunogenicity at baseline in
efﬁcacy trials, the importance of examining immunogenicity in
dengue-naïve and dengue-primed individuals is clear.
Importantly, there is no established correlate of protection for
an effective dengue vaccine. Currently immunogenicity studies to
assess neutralizing antibodies for all four serotypes are required
to move forward with a vaccine candidate. Cellular immunity is
less often studied and could be equally important. Early studies of
CYD demonstrated strong antibody response to all serotypes, but in
large phase IIb and phase III trials DENV2 serotype speciﬁc vaccine
efﬁcacy was  not signiﬁcant [22,31]. It is unclear why the vaccine
was not efﬁcacious against DENV2 despite its ability to induce neu-
tralizing antibody. Studies are currently ongoing to investigate the
quality of the antibody elicited as well as the role of cytotoxic T
cell response in protection. Of note, the vast majority of CD8 T cell
epitopes for dengue are contained in the non-structural (NS) pro-
teins [68], which are lacking in CYD. Novel methods for evaluating
and characterizing immunogenicity are needed to better predict
efﬁcacy [69].
Because of the magnitude of the dengue problem worldwide,
more than one of these vaccine candidates will be needed to ensure
an adequate vaccine supply in the long run. As of this date, only the
Sanoﬁ CYD vaccine has made it through phase III trials. This vac-
cine has been shown to be safe and has different levels of efﬁcacy
against the four serotypes, with highest efﬁcacy against serotypes
3 and 4. In addition, it has been shown to have very high efﬁcacy
against severe clinical disease and hospitalization due to dengue
[31,33]. This vaccine has also been shown to work better in peo-
ple with some prior dengue immunity, and to be less efﬁcacious in
those with no prior dengue immunity. Mathematical modeling has
shown that a vaccine with suitable characteristics could be quite
effective in reducing overall dengue illness levels in populations
that receive such a vaccine over time by routine vaccination of chil-
dren with a single catch-up campaign in older children and possibly
adults [70,71]. Much more work needs to be done to determine how
dengue vaccines, once licensed, could be deployed, but it is clear
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